Browse the evidence

Genetic linkage near the TNF-alpha locus is associated with higher percent body fat in Pima Indians, suggesting a genetic contribution to obesity susceptibility in this population.

This research suggests that for Pima Indians, obesity may have a strong genetic basis linked to the TNF-alpha region. This doesn't mean weight loss is impossible, but it implies that biological factors play a significant role in body fat regulation for this group, potentially requiring tailored approaches to diet and activity.

Menstrual cycle phase and oral contraceptive use do not significantly influence exercise performance or muscular hypertrophy in response to resistance training.

Train consistently regardless of your cycle phase. There is no evidence that you will lose muscle gains or performance by training during your luteal phase or while on birth control. Focus on progressive overload and consistency rather than phase-specific modifications.

Basal muscle sympathetic nerve activity (MSNA) correlates positively with plasma leptin concentration in healthy men, suggesting leptin acts as a peripheral signal to increase sympathetic outflow.

This research suggests that higher body fat leads to higher leptin, which in turn stimulates your sympathetic nervous system (your 'fight or flight' energy expenditure system). While this is a natural regulatory mechanism, the correlation is moderate, meaning other factors also drive your metabolic rate. It highlights that obesity involves complex hormonal signaling, not just 'calories in vs. calories out' in isolation.

The Visceral Adiposity Index (VAI) is a superior surrogate marker for arterial stiffness compared to BMI or waist circumference, as it remains an independent predictor of increased brachial-ankle pulse wave velocity (baPWV) even after adjusting for confounding factors.

If you are concerned about heart health and obesity, relying solely on your weight (BMI) or waist size may be misleading. A more comprehensive index (VAI) that includes blood lipid levels (Triglycerides and HDL) alongside your waist and weight provides a better assessment of arterial stiffness risk, even if you appear metabolically healthy.

Brown adipose tissue (BAT) is present and metabolically active in adult humans, particularly after cold exposure, challenging the historical view that adult humans lack significant brown fat.

Recent evidence confirms that adult humans possess active brown adipose tissue, which can be stimulated by cold exposure. While this does not replace the need for diet and exercise, it suggests that cold exposure may be a valid adjunct strategy to increase energy expenditure by activating this tissue.

The transcription factor PRDM16 controls the bidirectional switch between skeletal muscle and brown adipose tissue, promoting brown adipogenesis.

PRDM16 is a key regulator of brown fat development in rodents. While it offers a promising molecular target for future obesity treatments, its direct application in humans is not yet established.

Short-term thyroxine (T4) supplementation (200 mg/day for 3 days) in healthy euthyroid males reduces skeletal muscle mitochondrial efficiency (state 3 respiration and RCR) by approximately 30% without altering ATP demand or exercise efficiency.

Taking T4 (thyroxine) for 3 days at a dose of 200 mg/day in healthy men does not improve exercise efficiency or resting metabolic rate significantly. However, it does reduce the efficiency of skeletal muscle mitochondria, meaning the muscles become less effective at producing ATP. This suggests that T4 supplementation in healthy individuals may impair mitochondrial function without providing metabolic or performance benefits.

Weight loss interventions induce significant but small changes in DNA methylation (DNAm) across the genome, and baseline DNAm levels at specific loci (e.g., TNF-α, LEP, CLOCK, PER2) can predict the magnitude of weight loss response.

Your body's epigenetic markers (DNA methylation) change when you lose weight, and your starting levels might predict how much weight you'll lose. While these changes are small on a genome-wide scale, specific markers like TNF-α and LEP show promise as predictors. This suggests personalized medicine may eventually use these markers to tailor weight loss strategies, but for now, standard interventions (diet/exercise/surgery) remain the primary lever.

Acute moderate-intensity endurance exercise increases nuclear p53 abundance in untrained human skeletal muscle, suggesting a pro-autophagy response to clear damaged components before mitochondrial biogenesis.

For untrained individuals, a single 60-minute moderate-intensity cardio session triggers a cellular cleanup process (autophagy) mediated by p53 moving to the cell nucleus. This cleanup likely happens before the muscle builds new mitochondria. To support this natural adaptation, ensure you are recovering adequately and maintaining consistent activity levels.

PP protects against beta-cell apoptosis and may improve insulin sensitivity by enhancing the availability of insulin receptors.

PP may protect beta-cells and improve insulin sensitivity, suggesting potential anti-diabetic benefits.

Weight loss in obese individuals fails to resolve visceral adipose tissue (VAT) inflammation because senescent CD153+ PD-1+ CD4+ T cells persist and continue to produce osteopontin, maintaining a chronic inflammatory loop despite fat mass reduction.

If you have been obese for a long time, simply losing weight may not fully restore your metabolic health because your body retains 'senescent' immune cells that keep you inflamed. To mitigate this, focus on strategies that reduce chronic inflammation (like exercise and anti-inflammatory diets) in addition to weight loss, as weight loss alone may not clear these persistent immune cells.

GLP-1 receptor agonists (specifically exenatide) reduce fat mass and energy intake in HO patients but do not significantly alter BMI compared to placebo in the short term, and may decrease total energy expenditure.

Exenatide may help reduce fat mass and waist size in HO, but it often fails to lower BMI significantly. It is not a magic bullet for HO and requires careful monitoring for side effects like nausea.

Setmelanotide (MC4R agonist) is effective in reducing hunger and BMI in patients with HO due to hypothalamic injury, particularly those with specific genetic defects or structural damage affecting the melanocortin pathway.

Setmelanotide is a promising new treatment for HO that targets the root cause (MC4R deficiency). It requires daily injections and may cause skin darkening, but it is one of the few treatments showing efficacy in reducing BMI in this specific population.

Exogenous administration of undercarboxylated osteocalcin (ucOC) improves whole-body and skeletal muscle glucose metabolism and insulin sensitivity in animal models, though human evidence remains discordant.

Current research suggests that bone-derived factors like osteocalcin may help regulate blood sugar, especially in muscle. However, because human studies are inconsistent, there is no specific protocol to manipulate osteocalcin levels for diabetes treatment yet. Focus on proven methods: exercise (which naturally increases ucOC) and maintaining healthy bone density.

Sclerostin levels are elevated in individuals with Type 2 Diabetes and insulin resistance, and blocking sclerostin signaling improves insulin sensitivity in animal models.

High levels of sclerostin are linked to insulin resistance. While drugs targeting sclerostin (like romosozumab) exist for osteoporosis, their metabolic benefits are still being studied. For now, exercise and weight management remain the best ways to improve insulin sensitivity.

GLP-1 receptor agonists (specifically exenatide) reduce body fat and waist circumference in patients with hypothalamic obesity, with greater adiposity reduction observed in those with more extensive hypothalamic damage.

For patients with hypothalamic obesity, weekly exenatide injections (2 mg) can significantly reduce body fat and waist circumference, even if BMI changes are modest. This treatment is particularly effective for those with severe hypothalamic damage, likely because it works through brain pathways outside the damaged area. Side effects are mostly gastrointestinal.

Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, reduces hunger and BMI in patients with hypothalamic obesity caused by acquired hypothalamic injury, marking a potential breakthrough for this condition.

Setmelanotide is an MC4R agonist that reduces hunger and BMI in patients with hypothalamic obesity. It is FDA-approved for genetic obesity and is showing effectiveness for acquired hypothalamic injury. A large Phase 3 trial is currently underway.

Skeletal muscle regeneration efficiency is time-of-day dependent, with injury occurring during the active phase (when satellite cell BMAL1 expression peaks) resulting in enhanced repair compared to injury during the inactive phase.

If you sustain a muscle injury or undergo strenuous exercise that causes damage, your body repairs the tissue more effectively during your active phase (typically daytime for humans). This is driven by satellite cell clocks peaking in activity (BMAL1) during this time. While you cannot control the injury, scheduling intense training sessions during your active phase may theoretically support faster or more robust repair compared to late-night sessions, though human data is still emerging.

Cry2 is critical for the circadian regulation of myogenic differentiation and fusion by maintaining Cyclin D1 expression and Tmem176b rhythmicity.

Cry2 helps coordinate the timing of muscle fiber fusion after injury. It ensures that cells don't exit the cell cycle too early and maintains the expression of genes needed for fibers to merge. Disruption of this clock component can lead to incomplete regeneration.

Acupuncture acts as a multi-targeted therapy for obesity by modulating the neuro-endocrine-immune interplay, specifically by regulating hypothalamic neuropeptides (increasing POMC/alpha-MSH, decreasing NPY/AgRP), improving leptin sensitivity, and reducing chronic low-grade inflammation.

If standard diet and exercise efforts are stalled by biological barriers like leptin resistance or chronic inflammation, acupuncture may serve as a complementary multi-targeted therapy. It works by regulating appetite hormones and reducing inflammation. However, because techniques and acupoints vary widely, consistency and professional guidance are key.

Elevated levels of acetylcarnitine (C2) are associated with an increased risk of cardiovascular disease in patients with type 2 diabetes mellitus.

If you have Type 2 Diabetes, ask your doctor about checking acylcarnitine levels, specifically acetylcarnitine (C2). High levels may signal a higher risk for heart disease, even if your weight (BMI) looks normal. This finding suggests that managing metabolic health goes beyond just weight control and might require looking at specific metabolic markers to prevent cardiovascular issues.

Prescription medication-driven weight loss (mdWL) using GLP-1 agonists causes facial aesthetic changes including skin laxity, hollowed cheeks, and pronounced wrinkles, primarily affecting superficial and deep fat pads rather than bone or muscle.

If you are losing weight rapidly with prescription medications like Ozempic or Wegovy, expect changes in your face, such as sagging skin or hollow cheeks, due to fat loss in specific facial layers. This is a common side effect of the medication's mechanism, not a sign of poor health. To manage this, consult an aesthetic provider about timing treatments (like fillers or skin tightening) to coincide with your weight stabilization, rather than during active rapid loss. Avoid terms like 'Ozempic face' and focus on 'mdWL' management to reduce stigma.

Injectable antiresorptive drugs (zoledronate, denosumab, romosozumab) are superior to oral bisphosphonates for preventing bone loss in long-duration space missions because they bypass gastrointestinal side effects and offer potent, sustained suppression of bone resorption.

For long-duration space travel, injectable bone-preserving drugs (zoledronate, denosumab, romosozumab) are preferred over oral options due to better efficacy and lack of gastrointestinal side effects. These drugs suppress bone resorption effectively with rare side effects when used for short durations (1-2 years).

Muscle wasting in space is primarily driven by depressed protein synthesis rather than excessive protein breakdown, and anabolic steroids are ineffective without concurrent resistance exercise.

To prevent muscle loss in space, resistance exercise is essential. Anabolic steroids may help but are weak alone and only effective when combined with strength training. The primary countermeasure remains physical exercise.